Virax Biolabs Group Ltd
VRAX
Detailliertes Diagramm anzeigen
0.628USD
-0.016-2.44%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
2.73MMarktkapitalisierung
--KGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-2.44%
5 Tage
+5.42%
1 Monat
-18.93%
6 Monate
-48.92%
Seit Jahresbeginn
-72.08%
1 Jahr
-75.17%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert: 2025-09-19Wichtige Einblicke
Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
0
Analysten
--
Aktuelles Rating
--
Kursziel
--
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
performance_growth_period
performance_growth_period_desc%!(EXTRA string=6.33K)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-0.39)
institutional_increasing_position
institutional_increasing_position_desc%!(EXTRA string=729.04K, string=16.92%)
institutional_hold%!(EXTRA string=James Simons)
institutional_hold_desc%!(EXTRA string=James Simons, string=0.00)
activity_increase
activity_increase_desc%!(EXTRA string=0.02)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
BörsenkürzelVRAX
UnternehmenVirax Biolabs Group Ltd
CEOMr. James Foster
Websitehttps://www.viraxbiolabs.com
Verwandte Finanzinstrumente
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
